▲ +313.14% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Iterum Therapeutics in the last 3 months. The average price target is $4.88, with a high forecast of $9.00 and a low forecast of $1.50. The average price target represents a 313.14% upside from the last price of $1.18.
The current consensus among 6 contributing investment analysts is to hold stock in Iterum Therapeutics.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.